ATE404208T1 - Uridin-therapie für patienten mit erhöhten purin- werten - Google Patents

Uridin-therapie für patienten mit erhöhten purin- werten

Info

Publication number
ATE404208T1
ATE404208T1 AT01979786T AT01979786T ATE404208T1 AT E404208 T1 ATE404208 T1 AT E404208T1 AT 01979786 T AT01979786 T AT 01979786T AT 01979786 T AT01979786 T AT 01979786T AT E404208 T1 ATE404208 T1 AT E404208T1
Authority
AT
Austria
Prior art keywords
patients
purine levels
uridine
elevated purine
elevated
Prior art date
Application number
AT01979786T
Other languages
English (en)
Inventor
Theodore Page
Deborah Brewer
Charles Moseley
Original Assignee
Repligen Corp
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24768963&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE404208(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Repligen Corp, Univ California filed Critical Repligen Corp
Application granted granted Critical
Publication of ATE404208T1 publication Critical patent/ATE404208T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT01979786T 2000-10-12 2001-10-12 Uridin-therapie für patienten mit erhöhten purin- werten ATE404208T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/689,551 US6727231B1 (en) 2000-10-12 2000-10-12 Uridine therapy for patients with elevated purine levels

Publications (1)

Publication Number Publication Date
ATE404208T1 true ATE404208T1 (de) 2008-08-15

Family

ID=24768963

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01979786T ATE404208T1 (de) 2000-10-12 2001-10-12 Uridin-therapie für patienten mit erhöhten purin- werten

Country Status (8)

Country Link
US (1) US6727231B1 (de)
EP (1) EP1324761B1 (de)
JP (1) JP2004527460A (de)
AT (1) ATE404208T1 (de)
AU (2) AU2002211711B2 (de)
CA (1) CA2425593A1 (de)
DE (1) DE60135358D1 (de)
WO (1) WO2002030354A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001068104A1 (en) * 2000-03-16 2001-09-20 The Mclean Hospital Corporation Compounds for the treatment of psychiatric or substance abuse disorders
US7440590B1 (en) * 2002-05-21 2008-10-21 University Of Kentucky Research Foundation System and technique for retrieving depth information about a surface by projecting a composite image of modulated light patterns
WO2005034874A2 (en) * 2003-10-08 2005-04-21 The Mclean Hospital Corporation Enhanced efficacy of omega-3 fatty acid therapy in the treatment of psychiatric disorders and other indications
JP2007508315A (ja) * 2003-10-08 2007-04-05 ザ マクレーン ホスピタル コーポレーション ω−3脂肪酸を含む組み合わせを用いて、精神障害、物質乱用障害、および他の障害を治療する方法
EP1765364A4 (de) * 2004-06-10 2010-09-22 Mclean Hospital Corp Pyrimidine, wie z:b: cytidin, bei der behandlung von patienten mit bipolaren störungen
US7737128B2 (en) * 2004-06-10 2010-06-15 The Mclean Hospital Corporation Pyrimidines, such as uridine, in treatments for patients with bipolar disorder
WO2006020703A1 (en) * 2004-08-11 2006-02-23 The Mclean Hospital Corporation Compounds for the treatment of marihuana dependence, withdrawal, and usage
WO2006030803A1 (ja) * 2004-09-17 2006-03-23 Kissei Pharmaceutical Co., Ltd. 8位修飾プリンヌクレオシド誘導体及びその医薬用途
CA2578953A1 (en) * 2004-09-23 2006-03-30 Merz Pharma Gmbh & Co. Kgaa Memantine for the treatment of childhood behavioral disorders
JP4778946B2 (ja) * 2007-12-03 2011-09-21 明治飼糧株式会社 血中尿酸値低下剤
US20100041621A1 (en) * 2008-08-15 2010-02-18 Perry Renshaw Methods and compositions for improving cognitive performance
WO2019094596A1 (en) * 2017-11-09 2019-05-16 The Trustees Of Columbia University In The City Of New York Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders
US11491120B2 (en) 2017-11-09 2022-11-08 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders in females
EP4012414A1 (de) * 2020-12-11 2022-06-15 Stalicla S.A. Diagnose von autismus-spektrum-störung phänotyp 1

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5470838A (en) 1987-10-28 1995-11-28 Pro-Neuron, Inc. Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine
IT1219667B (it) 1988-06-21 1990-05-24 Polifarma Spa Impiego di uridina nel trattamento farmacologico di disturbi dovuti ad alterato equilibrio dopaminergico
IL108524A0 (en) 1993-02-03 1994-05-30 Gensia Inc Imidazodiazepine analogs
US5962459A (en) 1996-05-28 1999-10-05 Polifarma S.P.A. Therapeutic active agent for treatment of neuron degenerative diseases
ATE374029T1 (de) * 1998-07-31 2007-10-15 Massachusetts Inst Technology Behandlung der alzheimer-krankheit durch erhöhung des cytidin-spiegels in vivo
US6472378B2 (en) 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
NZ513926A (en) * 1999-02-23 2001-09-28 Univ California Methods of treatment of mitochondrial disorders

Also Published As

Publication number Publication date
WO2002030354A2 (en) 2002-04-18
JP2004527460A (ja) 2004-09-09
EP1324761A2 (de) 2003-07-09
EP1324761B1 (de) 2008-08-13
CA2425593A1 (en) 2002-04-18
WO2002030354A3 (en) 2002-07-11
AU1171102A (en) 2002-04-22
AU2002211711B2 (en) 2007-05-17
US6727231B1 (en) 2004-04-27
EP1324761A4 (de) 2004-09-08
DE60135358D1 (de) 2008-09-25

Similar Documents

Publication Publication Date Title
DK1955700T3 (da) Terapeutisk behandling af androgenreceptor-betingede lidelser
AU2002366641A1 (en) Methods for inhibiting ocular processes
DE60135358D1 (de) Uridin-therapie für patienten mit erhöhten purin-werten
DE60037578D1 (de) Verwendung von triacetyluridin zur behandlung von mitochondrialen erkrankungen
IL249263A0 (en) Methods and systems for extracorporeal organ treatment
MY139142A (en) Short corridor progressive addition lenses with reduced unwanted astigmatism
ATE305932T1 (de) Rapanycin29-enole
TR200100267T2 (tr) İkameli anilid bileşimleri ve yöntemler.
ATE394121T1 (de) Verwendung von antikörpern gegen das muc18- antigen
DE69737592D1 (de) Mittel gegen juckreiz
EP1470146A4 (de) Antikörper gegen das muc18?antigen
NO20054343L (no) Behandling av immunologiske lidelser ved anvendelse av agonister av interleukin-21/interleukin-21 reseptor
EA200401341A1 (ru) Применение остеопротегерина для лечения и/или профилактики фиброзного заболевания
DE69927688D1 (de) Antivirales Mittel in Kombination mit Strahlentherapie zur Verwendung in der Behandlung von Krebs
EP1558766A4 (de) Verwendung von a33-antigenen und jam-it
WO2003057146A3 (en) Novel compositions and methods for cancer
EA200501528A1 (ru) Применение кластерина для лечения и/или профилактики периферических неврологических заболеваний
MXPA03010406A (es) Tratamiento novedoso para el desorden obsesivo-compulsivo (ocd) y desordenes relacionados con ocd.
WO2004047727A3 (en) Compositions and methods for diagnosing and treating mood disorders
PT1143917E (pt) Derivados anticonvulsionantes uteis no tratamento da perturbacao de stress pos-traumatico
PT1092040E (pt) Metodos de inibicao helicobacter pylori
FI20040531A7 (fi) Insuliiniresistenttien tilojen hoitaminen ja diagnosointi
PT1603544E (pt) Tratamento de problemas intestinais com n-2,3,3-tetrametilbiciclo 2.2.2. heptan-2-amina
NO20005548D0 (no) Mykobakterieinhibitorer
NO20060420L (no) 2-aminobenzoylderivater

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties